CytoSorbents Proudly Sponsors World Sepsis Day 2014, Celebration of Sepsis Heroes, and the Roger Bone Award

MONMOUTH JUNCTION, N.J., Sept. 18, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using its CytoSorb® blood purification technology to treat life-threatening inflammatory conditions such as sepsis, is a proud sponsor of:

• World Sepsis Day 2014 organized by the Global Sepsis Alliance
• The short film "97 seconds for sepsis" produced by the Global Sepsis Alliance
• The 3^rd Annual Celebration of Sepsis Heroes event hosted by the Sepsis Alliance tonight in New York City at Arena NYC (135 West 41^st Street) from 7:00-10:00 PM EDT with a keynote address by Mr. Paul Levy, former President and CEO of Beth Israel Deaconess Medical Center in Boston
• The Roger Bone Award, awarded by the German Sepsis Society to recognize an outstanding publication in clinical sepsis research for young scientists in German-speaking countries.  Dr. Bone was a pioneer in understanding the connection between uncontrolled inflammation and organ failure in sepsis pathology and one of the fathers of critical care immunotherapy
• Sepsis awareness and education at the University Medical Center Hamburg-Eppendorf

In addition, CytoSorbents' partners have also been active.

• Biocon Ltd, CytoSorbents' strategic partner in India, is also a sponsor of World Sepsis Day.  Biocon recently completed a five city tour in India, including the Delhi Society of Critical Care Medicine Conference, with Dr. med. Axel Nierhaus from University Medical Center Hamburg-Eppendorf, Germany.  The tour brought together more than 350 leading intensivists from across the country to learn more about CytoSorb® and its application in sepsis and other life-threatening illnesses  
• WMC Medical, the distributor of CytoSorb® in the Netherlands, also sponsored the 1^st Netherlands International Sepsis Symposium that took place last week.

Sepsis is a medical emergency that results from of an overzealous immune response to a serious infection, driven by a "cytokine storm," leading to widespread deadly inflammation that can cause multiple organ failure, immune paralysis, and death.  According to the Global Sepsis Alliance, sepsis afflicts 20-30 million people each year worldwide, and kills someone every few seconds, despite the use of antibiotics.

Dr. Phillip Chan, MD, PhD, CEO of CytoSorbents stated, "The impact of sepsis to human life is staggering and the problem continues to worsen. We hope to change this trend with our CytoSorb® therapy.  While antibiotics work to control the infection, CytoSorb® works to control the excessive inflammatory response through cytokine reduction, removal of bacterial toxins, and redirection of activated white blood cells to the area of infection and away from healthy organs.  In doing so, the goal is to prevent or treat organ failure, the leading cause of death in sepsis.  We are pleased to support the efforts of these organizations in the fight against this common foe."

About the Global Sepsis Alliance

The Global Sepsis Alliance (GSA) is a non-profit organization supporting the efforts of over 1 million caregivers in more than 70 countries as they seek to better understand and combat what many experts believe to be the leading cause of death worldwide: sepsis. The GSA has rallied the Global Sepsis Community to elevate public, philanthropic and governmental awareness, understanding and support of sepsis and to accelerate collaboration among researchers, clinicians, associated working groups and those dedicated to supporting them.

About the German Sepsis Society

The German Sepsis Society (GSS) is the primary medical society in Germany whose mission is to educate and increase public and professional awareness about sepsis.  The organization brings together leaders in sepsis research, diagnostics, treatment, and education in order to also encourage new research, recognize valuable scientific contributions, and foster collaborations to help save lives.  A major goal is to support the rapid implementation of effective sepsis diagnostics and therapies into the standard of care treatment for sepsis.  Members of the GSS have been heavily involved with SepNet, or the Sepsis Competence Network, a consortium of hospitals and investigators funded for 10 years by the German Federal Ministry of Education to conduct research and clinical trials in sepsis.  The GSS also initiated the foundation of the organization, German Sepsis Aid, by people who survived sepsis and their relatives, to provide assistance, information, and networking for those whose lives have been touched by sepsis.  For more information, visit www.sepsis-gesellschaft.de/DSG/Englisch

About the Sepsis Alliance™ and Sepsis Heroes Evening

The Sepsis Alliance is a charitable organization run by a team of dedicated laypeople and professionals who share a strong commitment to battling sepsis.  The goal is to raise awareness of sepsis through information and educational material so it can be detected and treated early enough that no harm is done.  The Sepsis Heroes Evening is an award reception, being held in New York City, designed to raise awareness of sepsis and to recognize the unique contributions of individuals who have committed their time and energy for the cause.  This year, Sepsis Alliance honors two organizations, Every Mother Counts and Intermountain Healthcare, and three individuals, Jeff and Helene Zehnder and Laura Messineo, for their contributions to increasing sepsis awareness and improving treatment response.   For more information, visit www.sepsisalliance.org

About World Sepsis Day

World Sepsis Day is an initiative of the Global Sepsis Alliance (GSA) and its founding non-profit members:  The World Federation of Societies of Intensive and Critical Care Medicine, the World Federation of Pediatric Intensive and Critical Care Societies, the World Federation of Critical Care Nurses, the International Sepsis Forum, and the Sepsis Alliance.  The goals of World Sepsis Day are to:

• Reduce the incidence of sepsis through effective prevention strategies
• Increase sepsis survival rates for all population groups around the world
• Provide better access to suitable rehabilitation services for people everywhere
• Increase awareness and understanding of sepsis among healthcare professionals and the general public

For more information, visit www.world-sepsis-day.org

About CytoSorbents Corporation

CytoSorbents Corporation is a critical care focused immunotherapy company using blood purification to control severe inflammation -- with the goal of preventing or treating multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company's flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website:  http://www.cytosorbents.com

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. Risk factors are detailed in the Company's Form 10-K filed with the SEC on March 31, 2014, which is available at http://www.sec.gov.

Logo - http://photos.prnewswire.com/prnh/20140408/MM00899LOGO

SOURCE CytoSorbents Corporation